CXCL13 shapes tertiary lymphoid structures and promotes response to immunotherapy in bladder cancer

Mathieu Rouanne; Nicholas Arpaia; Aurélien Marabelle

doi:10.1016/j.ejca.2021.03.054

CXCL13 shapes tertiary lymphoid structures and promotes response to immunotherapy in bladder cancer

Mathieu Rouanne, Nicholas Arpaia, Aurélien Marabelle

Research output: Contribution to journal › Editorial

22 Citations (Scopus)

Original language	English
Pages (from-to)	245-248
Number of pages	4
Journal	European Journal of Cancer
Volume	151
DOIs	https://doi.org/10.1016/j.ejca.2021.03.054
Publication status	Published - 1 Jul 2021

Keywords

Anti–PD-L1
Bladder cancer
CXCL13
Tertiary lymphoid structures

Access to Document

10.1016/j.ejca.2021.03.054

Cite this

@article{aa9c54966b20466381acf7b18f10dd8f,

title = "CXCL13 shapes tertiary lymphoid structures and promotes response to immunotherapy in bladder cancer",

keywords = "Anti–PD-L1, Bladder cancer, CXCL13, Tertiary lymphoid structures",

author = "Mathieu Rouanne and Nicholas Arpaia and Aur{\'e}lien Marabelle",

note = "Funding Information: Mathieu Rouanne has received pre-clinical and clinical research grants (institutional funding) from AstraZeneca and Ipsen . Nicholas Arpaia discloses a financial interest in GenCirq, Inc. Aur{\'e}lien Marabelle has received research grants from Astrazeneca , BMS , Boehringer Ingelheim , Janssen Cilag , Merck , Novartis , Pfizer , Roche , Sanofi ; has received Pre-Clinical and Clinical Research Grants (Institutional Funding) from Merus , BMS , Boehringer Ingelheim , Transgene , Fondation MSD Avenir , Sanofi ; is a member of Clinical Trial Steering Committee: NCT02528357 (GSK), NCT03334617 (AZ) and Data Safety and Monitoring Board: NCT02423863 (Sponsor: Oncovir), NCT03818685 (Sponsor: Centre L{\'e}on B{\'e}rard); has participated in Scientific Advisory Boards: Merck Serono, eTheRNA, Lytix pharma, Kyowa Kirin Pharma, Novartis, BMS, Symphogen, Genmab, Amgen, Biothera, Nektar, Tesaro/GSK, Oncosec, Pfizer, Seattle Genetics, Astra Zeneca/Medimmune, Servier, Gritstone, Molecular Partners, Bayer, Partner Therapeutics, Sanofi, Pierre Fabre, RedX pharma, OSE Immunotherapeutics, Medicxi, HiFiBio, IMCheck, MSD; has received teaching/speaker activities from Roche/Genentech, BMS, Merck (MSD), Merck Serono, Astra Zeneca/Medimmune, Amgen, Sanofi, Servier; has received fees for Scientific \& Medical Consulting: Roche, Pierre Fabre, Onxeo, EISAI, Bayer, Genticel, Rigontec, Daichii Sankyo, Imaxio, Sanofi/BioNTech, Molecular Partners, Pillar Partners, BPI, Faron; has received non-financial support (travel expenses) from Astra Zeneca, BMS, Merck (MSD), Roche; is co-founder and shareholder of Pegascy SAS \& PEGA-1 SAS; is patent holder: patent issued (not licensed): “Humanised and Chimeric Monoclonal Antibodies to CD81”, Stanford Office of Technology Licensing, 3000 El Camino Real, Bldg. 5, Suite 300, Palo Alto, CA 94306-2100. U.S. Application Serial No. 62/351,054. Funding Information: Mathieu Rouanne has received pre-clinical and clinical research grants (institutional funding) from AstraZeneca and Ipsen. Nicholas Arpaia discloses a financial interest in GenCirq, Inc. Aur?lien Marabelle has received research grants from Astrazeneca, BMS, Boehringer Ingelheim, Janssen Cilag, Merck, Novartis, Pfizer, Roche, Sanofi; has received Pre-Clinical and Clinical Research Grants (Institutional Funding) from Merus, BMS, Boehringer Ingelheim, Transgene, Fondation MSD Avenir, Sanofi; is a member of Clinical Trial Steering Committee: NCT02528357 (GSK), NCT03334617 (AZ) and Data Safety and Monitoring Board: NCT02423863 (Sponsor: Oncovir), NCT03818685 (Sponsor: Centre Le?on Be?rard); has participated in Scientific Advisory Boards: Merck Serono, eTheRNA, Lytix pharma, Kyowa Kirin Pharma, Novartis, BMS, Symphogen, Genmab, Amgen, Biothera, Nektar, Tesaro/GSK, Oncosec, Pfizer, Seattle Genetics, Astra Zeneca/Medimmune, Servier, Gritstone, Molecular Partners, Bayer, Partner Therapeutics, Sanofi, Pierre Fabre, RedX pharma, OSE Immunotherapeutics, Medicxi, HiFiBio, IMCheck, MSD; has received teaching/speaker activities from Roche/Genentech, BMS, Merck (MSD), Merck Serono, Astra Zeneca/Medimmune, Amgen, Sanofi, Servier; has received fees for Scientific \& Medical Consulting: Roche, Pierre Fabre, Onxeo, EISAI, Bayer, Genticel, Rigontec, Daichii Sankyo, Imaxio, Sanofi/BioNTech, Molecular Partners, Pillar Partners, BPI, Faron; has received non-financial support (travel expenses) from Astra Zeneca, BMS, Merck (MSD), Roche; is co-founder and shareholder of Pegascy SAS \& PEGA-1 SAS; is patent holder: patent issued (not licensed): ?Humanised and Chimeric Monoclonal Antibodies to CD81?, Stanford Office of Technology Licensing, 3000 El Camino Real, Bldg. 5, Suite 300, Palo Alto, CA 94306-2100. U.S. Application Serial No. 62/351,054.",

year = "2021",

month = jul,

day = "1",

doi = "10.1016/j.ejca.2021.03.054",

language = "English",

volume = "151",

pages = "245--248",

journal = "European Journal of Cancer",

issn = "0959-8049",

}

TY - JOUR

T1 - CXCL13 shapes tertiary lymphoid structures and promotes response to immunotherapy in bladder cancer

AU - Rouanne, Mathieu

AU - Arpaia, Nicholas

AU - Marabelle, Aurélien

N1 - Funding Information: Mathieu Rouanne has received pre-clinical and clinical research grants (institutional funding) from AstraZeneca and Ipsen . Nicholas Arpaia discloses a financial interest in GenCirq, Inc. Aurélien Marabelle has received research grants from Astrazeneca , BMS , Boehringer Ingelheim , Janssen Cilag , Merck , Novartis , Pfizer , Roche , Sanofi ; has received Pre-Clinical and Clinical Research Grants (Institutional Funding) from Merus , BMS , Boehringer Ingelheim , Transgene , Fondation MSD Avenir , Sanofi ; is a member of Clinical Trial Steering Committee: NCT02528357 (GSK), NCT03334617 (AZ) and Data Safety and Monitoring Board: NCT02423863 (Sponsor: Oncovir), NCT03818685 (Sponsor: Centre Léon Bérard); has participated in Scientific Advisory Boards: Merck Serono, eTheRNA, Lytix pharma, Kyowa Kirin Pharma, Novartis, BMS, Symphogen, Genmab, Amgen, Biothera, Nektar, Tesaro/GSK, Oncosec, Pfizer, Seattle Genetics, Astra Zeneca/Medimmune, Servier, Gritstone, Molecular Partners, Bayer, Partner Therapeutics, Sanofi, Pierre Fabre, RedX pharma, OSE Immunotherapeutics, Medicxi, HiFiBio, IMCheck, MSD; has received teaching/speaker activities from Roche/Genentech, BMS, Merck (MSD), Merck Serono, Astra Zeneca/Medimmune, Amgen, Sanofi, Servier; has received fees for Scientific & Medical Consulting: Roche, Pierre Fabre, Onxeo, EISAI, Bayer, Genticel, Rigontec, Daichii Sankyo, Imaxio, Sanofi/BioNTech, Molecular Partners, Pillar Partners, BPI, Faron; has received non-financial support (travel expenses) from Astra Zeneca, BMS, Merck (MSD), Roche; is co-founder and shareholder of Pegascy SAS & PEGA-1 SAS; is patent holder: patent issued (not licensed): “Humanised and Chimeric Monoclonal Antibodies to CD81”, Stanford Office of Technology Licensing, 3000 El Camino Real, Bldg. 5, Suite 300, Palo Alto, CA 94306-2100. U.S. Application Serial No. 62/351,054. Funding Information: Mathieu Rouanne has received pre-clinical and clinical research grants (institutional funding) from AstraZeneca and Ipsen. Nicholas Arpaia discloses a financial interest in GenCirq, Inc. Aur?lien Marabelle has received research grants from Astrazeneca, BMS, Boehringer Ingelheim, Janssen Cilag, Merck, Novartis, Pfizer, Roche, Sanofi; has received Pre-Clinical and Clinical Research Grants (Institutional Funding) from Merus, BMS, Boehringer Ingelheim, Transgene, Fondation MSD Avenir, Sanofi; is a member of Clinical Trial Steering Committee: NCT02528357 (GSK), NCT03334617 (AZ) and Data Safety and Monitoring Board: NCT02423863 (Sponsor: Oncovir), NCT03818685 (Sponsor: Centre Le?on Be?rard); has participated in Scientific Advisory Boards: Merck Serono, eTheRNA, Lytix pharma, Kyowa Kirin Pharma, Novartis, BMS, Symphogen, Genmab, Amgen, Biothera, Nektar, Tesaro/GSK, Oncosec, Pfizer, Seattle Genetics, Astra Zeneca/Medimmune, Servier, Gritstone, Molecular Partners, Bayer, Partner Therapeutics, Sanofi, Pierre Fabre, RedX pharma, OSE Immunotherapeutics, Medicxi, HiFiBio, IMCheck, MSD; has received teaching/speaker activities from Roche/Genentech, BMS, Merck (MSD), Merck Serono, Astra Zeneca/Medimmune, Amgen, Sanofi, Servier; has received fees for Scientific & Medical Consulting: Roche, Pierre Fabre, Onxeo, EISAI, Bayer, Genticel, Rigontec, Daichii Sankyo, Imaxio, Sanofi/BioNTech, Molecular Partners, Pillar Partners, BPI, Faron; has received non-financial support (travel expenses) from Astra Zeneca, BMS, Merck (MSD), Roche; is co-founder and shareholder of Pegascy SAS & PEGA-1 SAS; is patent holder: patent issued (not licensed): ?Humanised and Chimeric Monoclonal Antibodies to CD81?, Stanford Office of Technology Licensing, 3000 El Camino Real, Bldg. 5, Suite 300, Palo Alto, CA 94306-2100. U.S. Application Serial No. 62/351,054.

PY - 2021/7/1

Y1 - 2021/7/1

KW - Anti–PD-L1

KW - Bladder cancer

KW - CXCL13

KW - Tertiary lymphoid structures

UR - http://www.scopus.com/inward/record.url?scp=85106322935&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2021.03.054

DO - 10.1016/j.ejca.2021.03.054

M3 - Editorial

C2 - 33972155

AN - SCOPUS:85106322935

SN - 0959-8049

VL - 151

SP - 245

EP - 248

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -

CXCL13 shapes tertiary lymphoid structures and promotes response to immunotherapy in bladder cancer

Keywords

Access to Document

Other files and links

Cite this